CG Oncology: Funding, Investors & Team (Sep 2026)
A privately held oncolytic immunotherapy firm called CG Oncology is dedicated to creating bladder-saving treatments for people with bladder cancer. At CG Oncology, we envision a world in which people with urologic cancer can use our cutting-edge treatments to live and work with greater dignity and quality of life. In a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer, our lead candidate, CG0070, is an intravesically given oncolytic immunotherapy drug. KEYTRUDA® (pembrolizumab) and CG0070 are both being tested in a Phase 2 study for the same indication. Combining CG0070 and OPDIVO® is being tested for other kinds of bladder cancer (nivolumab)
CG Oncology has raised $120M across 1 funding round on record, the most recent a Series E of $120M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CG Oncology Company Profile and Key Stats
Latest funding round on record: Nov 2022.
CG Oncology Funding Rounds
CG Oncology Founders and Leadership Team
No contact details are on record for this team yet.
CG Oncology Funding Compared to Other Biotechnology Startups
CG Oncology's latest round of $120M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CG Oncology in Biotechnology and Irvine
Companies Similar to CG Oncology
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
CG Oncology Funding FAQs
What does CG Oncology do?
A privately held oncolytic immunotherapy firm called CG Oncology is dedicated to creating bladder-saving treatments for people with bladder cancer. At CG Oncology, we envision a world in which people with urologic cancer can use our cutting-edge treatments to live and work with greater dignity and quality of life. In a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer, our lead candidate, CG0070, is an intravesically given oncolytic immunotherapy drug. KEYTRUDA® (pembrolizumab) and CG0070 are both being tested in a Phase 2 study for the same indication. Combining CG0070 and OPDIVO® is being tested for other kinds of bladder cancer (nivolumab)
How much funding has CG Oncology raised?
CG Oncology has raised $120M across 1 round on record. The most recent is a Series E of $120M announced in Nov 2022.
When did CG Oncology last raise funding?
CG Oncology's most recent funding round on record is a Series E of $120M, announced in Nov 2022.
Who is the CEO of CG Oncology?
Alex Yeung is listed as CEO at CG Oncology.
Where is CG Oncology headquartered?
CG Oncology is based in Irvine, California, United States.
How many employees does CG Oncology have?
CG Oncology is in the 11-50 employee band.
How does CG Oncology's funding compare to other Biotechnology startups?
CG Oncology's latest round of $120M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's CG Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CG Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.